{"id":"NCT03960957","sponsor":"Galderma R&D","briefTitle":"Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-06-17","primaryCompletion":"2019-09-27","completion":"2020-04-16","firstPosted":"2019-05-23","resultsPosted":"2021-05-11","lastUpdate":"2022-08-26"},"enrollment":301,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Glabellar Frown Lines"],"interventions":[{"type":"BIOLOGICAL","name":"AbobotulinumtoxinA","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Experimental","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"An interventional phase 3 study to evaluate efficacy and safety of a new dilution and injection volume of AbobotulinumtoxinA treatment for glabellar lines","primaryOutcome":{"measure":"Evaluate Composite Responder Rate at Month 1 for a Single Dose of AbobotulinumtoxinA Compared to Placebo","timeFrame":"Month 1 after treatment","effectByArm":[{"arm":"Experimental","deltaMin":142,"sd":null},{"arm":"Placebo","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":1},"locations":{"siteCount":11,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":223},"commonTop":["Headache","Eyelid ptosis","injection site pain","Migraine","Injection site reaction"]}}